MA51681A - Anticorps humains contre l'hémagglutinine de la grippe - Google Patents

Anticorps humains contre l'hémagglutinine de la grippe

Info

Publication number
MA51681A
MA51681A MA051681A MA51681A MA51681A MA 51681 A MA51681 A MA 51681A MA 051681 A MA051681 A MA 051681A MA 51681 A MA51681 A MA 51681A MA 51681 A MA51681 A MA 51681A
Authority
MA
Morocco
Prior art keywords
human antibodies
antibodies against
influenza hemagglutinin
against influenza
hemagglutinin
Prior art date
Application number
MA051681A
Other languages
English (en)
French (fr)
Inventor
William Olson
Lisa A Purcell
Jonathan Viau
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA51681A publication Critical patent/MA51681A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA051681A 2018-01-26 2019-01-24 Anticorps humains contre l'hémagglutinine de la grippe MA51681A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862622480P 2018-01-26 2018-01-26

Publications (1)

Publication Number Publication Date
MA51681A true MA51681A (fr) 2021-05-05

Family

ID=66286952

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051681A MA51681A (fr) 2018-01-26 2019-01-24 Anticorps humains contre l'hémagglutinine de la grippe

Country Status (17)

Country Link
US (1) US11780907B2 (https=)
EP (1) EP3743442A1 (https=)
JP (2) JP7372925B2 (https=)
KR (1) KR102820941B1 (https=)
CN (1) CN111670195B (https=)
AU (1) AU2019212480B2 (https=)
BR (1) BR112020014849A2 (https=)
CA (1) CA3088194A1 (https=)
CL (1) CL2020001884A1 (https=)
CO (1) CO2020009043A2 (https=)
EA (1) EA202091563A1 (https=)
IL (1) IL275884B2 (https=)
MA (1) MA51681A (https=)
MX (1) MX2020007772A (https=)
PH (1) PH12020551051A1 (https=)
SG (1) SG11202006379UA (https=)
WO (1) WO2019147867A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292353A (en) * 2019-10-28 2022-06-01 Regeneron Pharma Anti-haemagglutinin antibodies and methods of using them
WO2021202235A1 (en) * 2020-04-01 2021-10-07 University Of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
CA3197537A1 (en) * 2020-11-23 2022-05-27 Davide Corti Antibodies against influenza a viruses
WO2023201306A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections
KR102835659B1 (ko) * 2024-11-28 2025-07-24 주식회사 마크헬츠 인플루엔자 a형 바이러스 검출용 항체 및 이의 용도

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
JP2008539785A (ja) * 2005-05-16 2008-11-20 モルフォテック、インク． 所望の表現型を示す細胞を選択するために制御されたベクター
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
EP2450377A1 (en) 2006-09-07 2012-05-09 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
EP1947423A1 (en) 2007-01-16 2008-07-23 Sony Deutschland Gmbh Distance, orientation and velocity sensitive controller
CA2687147C (en) 2007-05-11 2016-08-23 Temasek Life Sciences Laboratory Limited H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance
AU2008297594B2 (en) 2007-09-13 2013-06-20 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof
EP2207804B1 (en) 2007-09-13 2015-07-22 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof
RU2010127156A (ru) 2007-12-06 2012-01-20 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Антитела против вируса гриппа и их применение
EP2250197B1 (en) 2008-02-05 2016-05-11 Temasek Life Sciences Laboratory Limited Binding protein and epitope-blocking elisa for the universal detection of h5-subtype influenza viruses
JP2011516423A (ja) 2008-03-28 2011-05-26 シー レーン バイオテクノロジーズ， エルエルシー ウイルス抗原に対する中和分子
CA2731686C (en) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
EP4071169A2 (en) 2008-08-25 2022-10-12 Dana Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
AU2008365616A1 (en) 2008-12-24 2011-08-11 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
EP2380976A4 (en) 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
CA2761648C (en) 2009-05-11 2019-03-12 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
EP3098236A1 (en) 2010-03-08 2016-11-30 Celltrion, Inc. Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
KR101849738B1 (ko) 2010-06-17 2018-04-17 트렐리스 바이오싸이언스 인코포레이티드 수동 인플루엔자 면역에 유용한 항체
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012045001A2 (en) 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
US8961978B2 (en) 2011-07-14 2015-02-24 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
ITRM20110606A1 (it) 2011-11-16 2013-05-17 Ist Superiore Sanita Peptidi della lattoferrina per lo uso come inibitori ad ampio spettro dellainfezione da virus della influenza.
EP2785737A2 (en) 2011-12-02 2014-10-08 AIMM Therapeutics B.V. Influenza a virus specific antibodies
MX367743B (es) 2011-12-05 2019-09-04 Trellis Bioscience Llc Anticuerpos utiles para la inmunizacion pasiva de influenza.
SG11201405226TA (en) 2012-03-08 2014-11-27 Crucell Holland Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CN104968367B (zh) 2012-11-13 2018-04-13 弗·哈夫曼-拉罗切有限公司 抗血凝素抗体和使用方法
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
SI3052192T1 (sl) * 2013-10-02 2020-11-30 Medimmune, Llc Nevtralizarijoča protitelesa proti-influenci A in njihove uporabe
JP6712428B2 (ja) * 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
TW201620932A (zh) 2014-03-27 2016-06-16 建南德克公司 抗－ｂ型流感病毒血球凝集素抗體及其使用方法
CN104031118B (zh) 2014-06-19 2016-04-13 天津大学 鼠多瘤病毒衣壳粒的新型亲和肽配基及其设计筛选方法
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US10435462B2 (en) 2015-03-31 2019-10-08 Viro Dynamics Corporation Hybrid influenza seed viruses, compositions thereof, and use thereof in the diagnosis or therapy of influenza
KR102668588B1 (ko) 2015-04-08 2024-05-22 다나-파버 캔서 인스티튜트 인크. 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
HUE056407T2 (hu) 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
WO2020221450A1 (en) 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies and methods for treatment of influenza a infection

Also Published As

Publication number Publication date
IL275884A (en) 2020-08-31
CO2020009043A2 (es) 2020-07-31
US20210371505A1 (en) 2021-12-02
AU2019212480B2 (en) 2025-07-24
JP7372925B2 (ja) 2023-11-01
KR102820941B1 (ko) 2025-06-16
IL275884B1 (en) 2024-07-01
EP3743442A1 (en) 2020-12-02
IL275884B2 (en) 2024-11-01
CA3088194A1 (en) 2019-08-01
CN111670195B (zh) 2024-08-13
WO2019147867A9 (en) 2019-11-07
BR112020014849A2 (pt) 2020-12-08
KR20200115517A (ko) 2020-10-07
JP2023060018A (ja) 2023-04-27
PH12020551051A1 (en) 2021-08-23
US11780907B2 (en) 2023-10-10
WO2019147867A1 (en) 2019-08-01
JP2021511043A (ja) 2021-05-06
EA202091563A1 (ru) 2020-10-08
CN111670195A (zh) 2020-09-15
CL2020001884A1 (es) 2020-12-11
AU2019212480A1 (en) 2020-09-10
MX2020007772A (es) 2020-09-18
SG11202006379UA (en) 2020-07-29

Similar Documents

Publication Publication Date Title
MA49043A (fr) Formulation stable d'anticorps
MA51681A (fr) Anticorps humains contre l'hémagglutinine de la grippe
EP3618871A4 (en) FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
EP3700416A4 (en) PRE-CONNECTED ANALYSIS SENSORS
EP3635724A4 (en) OBJECT TRACKING METHODS
MA43108A (fr) Anticorps neutralisant le virus syncytial respiratoire humain
MA41937A (fr) Conjugués de médicaments comprenant des anticorps contre la claudine 18.2
MA39803A (fr) Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3496753A4 (en) PD-1 ANTIBODY FORMULATION
EP3807318A4 (en) MULTISPECIFIC ANTIBODY CONSTRUCTS
MA54052A (fr) Formulation d'anticorps
EP3529009A4 (en) PEOPLE FOLLOWING ROBOT
MA51903A (fr) Formulations d'anticorps b7-h4
EP3814509A4 (en) INFLUENCE VIRUS HEMAGGLUTININ MUTANTS
MA54139A (fr) Formulation d'anticorps
EP3837286A4 (en) ANTIBODIES TO HUMAN ZNT8
EP3927729A4 (en) Therapeutic antibody formulation
EP3735987A4 (en) AMBANITIN ANTIBODY CONJUGATE
EP3849612A4 (en) ANTI-HIV ANTIBODIES 10-1074 VARIANTS
MA54097A (fr) Anticorps anti-fn14 humain
EP3885362A4 (en) ANTIBODY CONJUGATE
MA53466A (fr) Formulation stable d'anticorps anti-osmr
EP3833691A4 (en) HUMAN PD-L1 ANTIBODIES
MA46642A (fr) Promédicaments d'inhibiteurs de la kallicréine